June 26, 2012
Amylin Pharmaceuticals Inc. was hit Monday with a shareholder derivative lawsuit accusing the company's directors of secretly rejecting a $3.5 billion Bristol-Myers Squibb Co. takeover offer to keep the share price low while they loaded up on stock options.